NNNN - Anbio Biotechnology
6.53
-0.170 -2.603%
Share volume: 24,925
Last Updated: 04-25-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
0.03%
PREVIOUS CLOSE
CHG
CHG%
$6.70
-0.17
-0.03%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
-4.67%
1 Month
-13.51%
3 Months
13.17%
6 Months
13.17%
1 Year
13.17%
2 Year
13.17%
Key data
Stock price
$6.53
DAY RANGE
$6.15 - $6.77
52 WEEK RANGE
$5.18 - $7.82
52 WEEK CHANGE
$13.17
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Michael Lau
Region: US
Website:
Employees: 27
IPO year: 2025
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing
Region: US
Website:
Employees: 27
IPO year: 2025
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our principal executive offices are located at Wilhelm Gutbrod Str 21B, 60437, Frankfurt am Main, Germany.
Recent news
